摘要：近日，“2025年中欧血液与骨髓移植科学会议”在广州成功召开。本次会议由中国医疗保健国际交流促进会血液学分会和欧洲血液和骨髓移植协会基金会（荷兰）上海代表处共同主办，国家血液系统疾病临床医学研究中心-北京大学血液病研究所、中山大学肿瘤防治中心和中南大学湘雅二医

编者按：近日，“2025年中欧血液与骨髓移植科学会议”在广州成功召开。本次会议由中国医疗保健国际交流促进会血液学分会和欧洲血液和骨髓移植协会基金会（荷兰）上海代表处共同主办，国家血液系统疾病临床医学研究中心-北京大学血液病研究所、中山大学肿瘤防治中心和中南大学湘雅二医院共同承办。大会汇聚中欧血液与骨髓移植、细胞治疗等领域的众多顶尖专家学者，围绕学术前沿深入交流，分享最新研究成果。《肿瘤瞭望-血液时讯》现场对本次会议欧方主席之一——欧洲血液与骨髓移植协会（EBMT）现任主席、西班牙加泰罗尼亚肿瘤研究所Anna Sureda教授进行专访，请她分享此次参会的深刻感受，并就中欧移植合作前景、CAR-T等新兴疗法的整合应用，以及提升资源有限地区治疗可及性等话题发表前瞻性的观点。

《肿瘤瞭望-血液时讯》：本次来到中国参加中欧血液与骨髓移植科学会议，您有哪些特别的感受？同时，您对中欧在造血干细胞移植领域加强学术交流与临床合作有何期待？

Anna Sureda教授：首先，非常感谢此次采访。我在三天前抵达中国，先后参观了佛山和广州。中国医生和研究团队在科研与临床研究方面展现出的专业水平与卓越能力，令我印象非常深刻。我认为，今天举办的这一科学论坛不仅是一个促进学术交流、分享科研成果的宝贵平台，也为推动未来的国际合作、培养青年人才、促进科研教育发展提供了重要契机。我非常希望，未来几年我们能够进一步高效化这种合作，不断提升这一科学论坛的影响力，并在全年开展更多形式多样、内容丰富的科研与教育活动，为血液移植事业的发展作出更大贡献。

Oncology Frontier-Hematology Frontier：As you visit China for the China-Europe Scientific Conference on Hematology and Stem Cell Transplantation, what are your impressions? What are your hopes for strengthening academic exchange and clinical collaboration between China and Europe in this field?

Professor Anna Sureda：So thank you very much, first of all, for the interview. So I arrived here three days ago and I visited first of all Foshan and now here in Guangzhou. I have to say that I am very positively impressed by the high level of the scientific and clinical research with the different Chinese physicians and the different Chinese groups.I think that the scientific forum that we are having today is the perfect place to exchange science, to try to improve collaboration in the future and to foster education and scientific processes within our young colleagues.So I'm really very much hoping that in the near future, in the next years, we are able to streamline this collaboration to make even this scientific forum more impactful and even to develop additional educational scientific activities over the year.

《肿瘤瞭望-血液时讯》：近年来，随着移植技术的不断革新，包括预处理方案优化、供者类型多样化以及并发症管理的进步，造血干细胞移植的疗效不断提升。您认为当前最具突破性的进展是什么？这些变化对患者产生了哪些深远影响？

Anna Sureda教授：我认为，我们正迈入一个细胞治疗的全新时代。多年来，自体和异基因造血干细胞移植一直是细胞治疗的两大核心手段。而近年来，随着免疫治疗的快速发展，尤其是自体CAR-T细胞治疗在临床中的广泛应用，为我们带来了新的希望。当前，CAR-T细胞治疗已被广泛用于淋巴瘤、B细胞急性淋巴细胞白血病以及多发性骨髓瘤等疾病，取得了令人鼓舞的疗效。

结合您刚才提到的各项研究进展，我们在造血干细胞移植患者的疗效方面也实现了显著提升。当前，我们正积极探索如何将CAR-T细胞治疗更合理地纳入造血干细胞移植相关的治疗流程中，以进一步改善患者的长期预后。在某些特定情况下，CAR-T治疗也有可能减少对造血干细胞移植的依赖，这将为患者带来更加个体化、精准化的治疗选择。

Oncology Frontier-Hematology Frontier：With ongoing advancements in transplant techniques—such as improved conditioning regimens, expanded donor options, and better management of complications—treatment outcomes have greatly improved. What do you consider the most groundbreaking progress so far, and how has it impacted patients?

Professor Anna Sureda：So I think that we are entering a kind of new era when we talk about cellular therapy. So for many years, autologous and allogeneic stem cell transplantation have been the two major types of cellular therapies. Nowadays we have additional immunotherapy treatments that are starting to be used. Basically, the introduction of autologous CAR-T cells, basically in patients with lymphomas, in patients with B-cell acute lymphoblastic leukemia, and in patients with multiple myeloma. We have been able to improve the outcome of patients being treated with stem cell transplantation with all the advances that you have mentioned. And nowadays we are experimenting how we can include CAR-T cells in the treatment landscape of these patients to try to improve the long-term outcomes and in some cases, of course, reducing the number of patients being treated with stem cell transplantation.

《肿瘤瞭望-血液时讯》：在全球范围内，造血干细胞移植的可及性和标准化仍面临挑战，尤其是在资源有限的地区。作为EBMT主席，您能否分享EBMT在推动移植治疗规范化、促进国际合作方面的主要策略？您认为欧洲有哪些经验值得全球同行借鉴？

Anna Sureda教授：EBMT的使命是通过科学研究、教育培训，以及认证与质量控制体系的建立，持续提升患者的医疗质量与照护水平。我们始终致力于推动全球化发展，尽管这一过程面临诸多挑战，但我们始终努力将我们的理念和实践推广到那些干细胞移植尚未普及，或质量体系尚未完善的国家和地区。

在这一过程中，教育始终是我们工作的重点之一。我们持续开展多种形式的教育项目，既包括线下的面对面课程，也包括通过线上平台组织的虚拟培训活动。同时，我们也在积极改善不同地区医生和护士参与线下会议的可及性与便利性，力求为更多医疗从业者提供高质量的学习和交流机会。

此外，EBMT也高度重视国际合作，我们欢迎来自全球各地的专业人士参与我们的科学项目。我相信，这种跨区域的协作不仅有助于推动造血干细胞移植在更多地区的开展，也将进一步提升全球移植水平和患者的治疗效果。

Oncology Frontier-Hematology Frontier：Globally, there are still challenges in terms of access to and standardization of hematopoietic cell transplantation, especially in resource-limited regions. As President of the EBMT, could you share the main strategies EBMT is implementing to promote treatment standardization and international collaboration? What lessons from Europe do you think could be valuable for other regions?

Professor Anna Sureda：So the EBMT mission is to improve the patient care through science and through education and also through accreditation and quality control strategies. So we try to be as global as possible although this is easy to say, difficult to do, but we try to bring our mission to countries or to areas around the globe where stem cell transplantation is not an option or eventually the quality control processes are not being put in place. We try to do that through education, so we have quite a rich portfolio of educational activities, face-to-face educational activities, but also virtual educational activities through the virtual platform. And we also try to improve the attendance and to facilitate the attendance of physicians and nurses from different regions to our face-to-face meetings. Of course, EBMT is also open to receive collaboration from professionals from other areas in scientific projects and I think that in this way we help to implement the stem cell transplantation in areas where it's not so implemented and to improve the results of stem cell transplantation.

《肿瘤瞭望-血液时讯》：面对精准医学、免疫治疗等新兴理念的迅猛发展，造血干细胞移植也正站在转型的关键节点。请问您如何看待未来十年该领域可能面临的主要挑战？又有哪些值得我们特别期待的技术或模式上的突破？

Anna Sureda教授：展望未来几年，我认为自体造血干细胞移植的应用可能会逐渐减少，这主要是由于CAR-T等新型细胞治疗手段在淋巴瘤和多发性骨髓瘤等疾病中的快速发展和明确定位所带来的影响。我们亟需进一步提升CAR-T细胞治疗的疗效，降低其毒副作用，从而使其在临床上更加安全、有效，真正造福更多患者。

至于异基因造血干细胞移植，我希望未来能够建立更加优化的治疗策略，使其在治疗体系中发挥更大作用，并尽可能降低复发风险。尽管我们已经通过减低强度的预处理方案，在一定程度上减少了非复发相关死亡率，但复发依然是当前异基因造血干细胞移植中面临的主要挑战。

我们正在迈入或者已经进入一个靶向治疗的时代。在这样的背景下，从细胞治疗的角度出发，如何将靶向治疗策略有效与造血干细胞移植平台相结合，将是我们提升疗效、改善患者长期预后的关键方向。

Oncology Frontier-Hematology Frontier：As precision medicine and immunotherapies continue to evolve, hematopoietic cell transplantation stands at a pivotal point of transformation. Looking ahead to the next decade, what do you consider the main challenges facing the field? And what breakthroughs—technological or conceptual—do you find most promising and worth anticipating?

Professor Anna Sureda：So I think that if I have to look into the future, I would say that probably the use of autologous stem cell transplantation is going to decrease in the next few years, basically because of the advance and the positioning of other cellular therapy, such as CAR-T cells, basically in the field of lymphomas and multiple myelomas. We will have to improve the efficacy and decrease the toxicity of CAR-T cells to make them more effective and less toxic and more safe for the patients. If we talk about allogeneic stem cell transplant, I hope that we can develop better treatment strategies integrated into the allogeneic stem cell transplantation platform to try to decrease as much as possible relapse rate. We have been able to decrease non-relapse mortality with the use of reduced-intensity conditioning regimens but relapse rate still represents the major cause of failure of the treatment in our patients that are candidates for an allogeneic stem cell transplant. And we are entering or we are already in the era of targeted therapies so it would be important from a cellular therapy perspective and point of view to try to integrate targeted therapies with transplantation platforms to increase the efficacy of the process itself and to improve the long-term outcome of the patients.

来源：肿瘤瞭望